TrialBMC infectious diseases2005

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Philip H Keiser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.